SEATTLE, June 01, 2021, (MEDGADGET) — Overview:
In clinical practice, managing patients with chronic respiratory conditions has been a challenge. Multidrug-resistant infections such as Pseudomonas aeruginosa, Burkholderia fungi, Methicillin-resistant Staphylococcus aureus and non-tuberculous Mycobacteria must be deal with in conditions like cystic fibrosis (CF) and non-CF bronchiectasis (NTM). To address these issues, scientists created a novel antimicrobial drug synthesis and deliver drugs to the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. Inhaling antibiotics are used to optimize drug transmission to the infection’s target spot, the airways, while minimizing the risk of systemic side effects.
The global inhaled antibiotics market size was valued around US$ 1,094.6 million in 2019 and is expected to register a CAGR over 6.3% during the forecast period (2020–2027).
Impact of Coronavirus (Covid-19) Pandemic:
The pandemic has spread to over 100 countries since the COVID-19 virus outbreak in December 2019, prompting the World Health Organization to declare it a public health emergency. For instance, according to the World Health Organization report, as of May 15, 2020, there are 4,307,287 individuals affected with coronavirus, globally. The worldwide effects of the coronavirus disease 2019 (COVID-19) has already started to affect all around, and the global inhaled antibiotics market will be greatly impacted in 2020. Increased COVID-19 occurrence will have a global economic effect by directly impacting commodity development and by creating supply chain and market disruption, and having a financial impact on businesses and financial markets.
For More Information, Request Sample Copy Of Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/3980
Drivers:
Rising prevalence of respiratory diseases is expected to propel the growth of the global inhaled antibiotics market during the forecast period.
Growing number of respiratory diseases such as chronic obstructive pulmonary diseases (COPD), asthma, and bronchitis is expected to propel the global inhaled antibiotics market growth during the forecast period. For instance, according to the World Health Organization Report May 2020, asthma is the most common chronic disease among children worldwide and around 339 million people were living with asthma in 2016. Similarly, according to the same source, over 80% of asthma-related deaths occur in low-and lower-middle income countries.
Furthermore, in 2016, according to the World Health organization 2017 report, around 251 million cases of chronic obstructive pulmonary diseases were found globally and around 3.17 million deaths were caused by chronic obstructive pulmonary diseases in 2015. However, according to the same source, over 90% of COPD deaths occur in low and middle income countries.
Rise in new product releases and approvals is expected to propel the global inhaled antibiotics market growth during the forecast period.
Major players dominating in the global inhaled antibiotics market are concentrating on new product releases, to broaden their product range and grow their footprint in the global market. For instance, in October 2017, Polyphor, a Swiss specialty pharmaceutical company, launched an inhaled form of the investigational antibiotic murepavadin (POL7080). Murepavadin, a type of outer membrane protein targeting antibiotic (OMPTA), acts specifically against the bacterial strain Pseudomonas aeruginosa, this strain has been observed in patients with a variety of lung disorders, including cystic fibrosis and non-cystic fibrosis-related bronchiectasis.
Moreover, In February 2016, Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., received approval from Health Canada for the application of its generic version of PrTeva-Tobramycin Inhalation Solution. This respiratory antibiotic is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3980
Furthermore, in April 2016, Raptor Pharmaceutical Corp., a biopharmaceutical company, launched its QUINSAIR (levofloxacin inhalation solution) in Germany and Denmark. It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections caused due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).
Restraint:
Moreover, medication inhalation side effects and the lack of a single successful inhaler system that can handle a wide variety of diseases, are expected to hinder the growth of the global inhaled antibiotics market.
Market Segmentation:
- By Product Type:Aerosol, Dry Powder Formulation, and Spray.
- By Application:Pneumonia, Asthma, Bronchitis, Others.
- By Distribution Channel:Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
Key Players:
Some of the key players in the global inhaled antibiotics market such as Aradigm, Lupin Ltd., Pharmaxis Ltd, Pharmaero, Insmed Incorporated, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Gilead Sciences, and Polyphor.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/inhaled-antibiotics-market-3248
Detailed Segmentation:
- Global Inhaled Antibiotics Market, By Product Type:
- Aerosol
- Dry Powder Formulation
- Spray
- Global Inhaled Antibiotics Market, By Application:
- Pneumonia
- Asthma
- Bronchitis
- Others
- Global Inhaled Antibiotics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Inhaled Antibiotics Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
Other Exclusive Reports:
Polyether Antibiotics Promising Growth Factors, Leading Players, Future Prospectus By 2027 – 2021
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837